Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
2,001-2,050 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__88_C3,5 | Lung | Primary cancer | 2,395 | Stromal | 32.2% | 0.50 | 0.80 |
| NSCLC_38242124__IMC__88_C3,6 | Lung | Primary cancer | 3,905 | Immune | 27.3% | 0.51 | 0.78 |
| NSCLC_38242124__IMC__88_C3,7 | Lung | Primary cancer | 4,437 | Tumor/Malignant | 38.5% | 0.93 | 0.27 |
| NSCLC_38242124__IMC__88_C3,8 | Lung | Primary cancer | 2,655 | Stromal | 43.4% | 0.94 | 0.20 |
| NSCLC_38242124__IMC__88_C3,9 | Lung | Primary cancer | 825 | Tumor/Malignant | 54.5% | 0.96 | 0.14 |
| NSCLC_38242124__IMC__88_C4,1 | Lung | Primary cancer | 3,475 | Tumor/Malignant | 58.8% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__88_C4,10 | Lung | Primary cancer | 4,221 | Immune | 42.2% | 0.95 | 0.14 |
| NSCLC_38242124__IMC__88_C4,11 | Lung | Primary cancer | 3,121 | Tumor/Malignant | 75.2% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__88_C4,13 | Lung | Primary cancer | 709 | Stromal | 38.5% | 0.81 | 0.45 |
| NSCLC_38242124__IMC__88_C4,14 | Lung | Primary cancer | 5,648 | Immune | 77.2% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__88_C4,15 | Lung | Primary cancer | 540 | Tumor/Malignant | 34.3% | 0.32 | 0.99 |
| NSCLC_38242124__IMC__88_C4,2 | Lung | Primary cancer | 2,398 | Tumor/Malignant | 59.9% | 0.94 | 0.19 |
| NSCLC_38242124__IMC__88_C4,3 | Lung | Primary cancer | 2,635 | Tumor/Malignant | 59.5% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__88_C4,4 | Lung | Primary cancer | 392 | Stromal | 41.6% | 0.87 | 0.37 |
| NSCLC_38242124__IMC__88_C4,5 | Lung | Primary cancer | 2,537 | Stromal | 42.6% | 0.88 | 0.36 |
| NSCLC_38242124__IMC__88_C4,6 | Lung | Primary cancer | 2,515 | Tumor/Malignant | 46.7% | 0.99 | 0.08 |
| NSCLC_38242124__IMC__88_C4,7 | Lung | Primary cancer | 118 | Stromal | 53.4% | 0.44 | 0.76 |
| NSCLC_38242124__IMC__88_C4,8 | Lung | Primary cancer | 2,727 | Tumor/Malignant | 50.7% | 0.97 | 0.10 |
| NSCLC_38242124__IMC__88_C4,9 | Lung | Primary cancer | 2,389 | Immune | 34.7% | 0.90 | 0.25 |
| NSCLC_38242124__IMC__88_C5,1 | Lung | Primary cancer | 3,087 | Stromal | 44.4% | 0.82 | 0.47 |
| NSCLC_38242124__IMC__88_C5,11 | Lung | Primary cancer | 2,509 | Tumor/Malignant | 39.2% | 1.00 | 0.04 |
| NSCLC_38242124__IMC__88_C5,12 | Lung | Primary cancer | 1,025 | Stromal | 38.0% | 0.99 | 0.15 |
| NSCLC_38242124__IMC__88_C5,13 | Lung | Primary cancer | 2,807 | Tumor/Malignant | 54.4% | 0.98 | 0.11 |
| NSCLC_38242124__IMC__88_C5,14 | Lung | Primary cancer | 5,840 | Immune | 88.9% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__88_C5,15 | Lung | Primary cancer | 363 | Other | 42.1% | 0.48 | 0.73 |
| NSCLC_38242124__IMC__88_C5,2 | Lung | Primary cancer | 55 | Tumor/Malignant | 94.5% | 0.79 | 0.34 |
| NSCLC_38242124__IMC__88_C5,3 | Lung | Primary cancer | 3,138 | Tumor/Malignant | 25.0% | 0.48 | 0.77 |
| NSCLC_38242124__IMC__88_C5,4 | Lung | Primary cancer | 2,948 | Tumor/Malignant | 76.5% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__88_C5,5 | Lung | Primary cancer | 2,510 | Stromal | 25.9% | 0.70 | 0.62 |
| NSCLC_38242124__IMC__88_C5,6 | Lung | Primary cancer | 2,005 | Tumor/Malignant | 67.2% | 0.95 | 0.14 |
| NSCLC_38242124__IMC__88_C5,8 | Lung | Primary cancer | 4,173 | Tumor/Malignant | 58.6% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__88_C5,9 | Lung | Primary cancer | 3,209 | Tumor/Malignant | 35.4% | 0.75 | 0.60 |
| NSCLC_38242124__IMC__88_C6,1 | Lung | Primary cancer | 1,348 | Tumor/Malignant | 65.1% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__88_C6,10 | Lung | Primary cancer | 117 | Tumor/Malignant | 54.7% | 0.88 | 0.26 |
| NSCLC_38242124__IMC__88_C6,11 | Lung | Primary cancer | 3,339 | Immune | 50.7% | 0.98 | 0.10 |
| NSCLC_38242124__IMC__88_C6,13 | Lung | Primary cancer | 2,332 | Tumor/Malignant | 79.5% | 0.98 | 0.06 |
| NSCLC_38242124__IMC__88_C6,14 | Lung | Primary cancer | 6,300 | Immune | 88.3% | 1.00 | 0.01 |
| NSCLC_38242124__IMC__88_C6,15 | Lung | Primary cancer | 4,927 | Tumor/Malignant | 77.8% | 0.98 | 0.06 |
| NSCLC_38242124__IMC__88_C6,2 | Lung | Primary cancer | 4,303 | Tumor/Malignant | 38.2% | 0.97 | 0.16 |
| NSCLC_38242124__IMC__88_C6,3 | Lung | Primary cancer | 193 | Tumor/Malignant | 72.5% | 0.92 | 0.14 |
| NSCLC_38242124__IMC__88_C6,5 | Lung | Primary cancer | 3,582 | Tumor/Malignant | 51.1% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__88_C6,6 | Lung | Primary cancer | 715 | Tumor/Malignant | 38.6% | 0.30 | 1.07 |
| NSCLC_38242124__IMC__88_C6,7 | Lung | Primary cancer | 2,882 | Immune | 27.0% | 0.49 | 0.83 |
| NSCLC_38242124__IMC__88_C6,9 | Lung | Primary cancer | 3,064 | Tumor/Malignant | 54.4% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__88_C7,1 | Lung | Primary cancer | 2,125 | Stromal | 28.8% | 0.79 | 0.53 |
| NSCLC_38242124__IMC__88_C7,10 | Lung | Primary cancer | 2,837 | Tumor/Malignant | 31.7% | 0.95 | 0.24 |
| NSCLC_38242124__IMC__88_C7,11 | Lung | Primary cancer | 3,953 | Tumor/Malignant | 51.6% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__88_C7,12 | Lung | Primary cancer | 3,520 | Tumor/Malignant | 88.0% | 1.00 | 0.01 |
| NSCLC_38242124__IMC__88_C7,13 | Lung | Primary cancer | 3,749 | Tumor/Malignant | 68.7% | 0.99 | 0.07 |
| NSCLC_38242124__IMC__88_C7,15 | Lung | Primary cancer | 866 | Stromal | 39.3% | 0.68 | 0.55 |